Corvus Pharmaceuticals (CRVS) 10-K10 Mar 172016 FY Annual reportFinancial data

Company Profile

Document and Entity Information

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
Document and Entity Information - USD ($) $ in Millions	Dec. 31, 2016	Mar. 10, 2017	Jun. 30, 2016
Document and Entity Information
Entity Registrant Name	Corvus Pharmaceuticals, Inc.
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Central Index Key	1,626,971
Document Type	10-K
Document Period End Date	Dec. 31, 2016
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Public Float			$ 118.6
Entity Common Stock, Shares Outstanding		20,933,387
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	FY

CONDENSED BALANCE SHEETS

CONDENSED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 5,050	$ 4,105
Marketable securities	129,846	90,281
Prepaid and other current assets	1,137	1,277
Total current assets	136,033	95,663
Property and equipment, net	3,248	1,845
Deferred offering costs		951
Other assets	869
Total assets	140,150	98,459
Current liabilities:
Accounts payable	1,900	1,575
Accrued and other liabilities	4,044	1,495
Total current liabilities	5,944	3,070
Other liabilities	1,405	710
Total liabilities	7,349	3,780
Commitments and contingencies (Note 13)
Convertible preferred stock: $0.0001 par value; 0 and 14,274,741 shares authorized at December 31, 2016 and December 31, 2015, respectively; 0 and 14,274,741 issued and outstanding at December 31, 2016 and December 31, 2015, respectively		125,780
Stockholders' equity (deficit):
Preferred stock: $0.0001 par value; 10,000,000 and 0 shares authorized at December 31, 2016 and December 31, 2015, respectively; 0 shares issued and outstanding at December 31, 2016 and December 31, 2015
Common stock: $0.0001 par value; 290,000,000 and 20,000,000 shares authorized at December 31, 2016 and 2015, respectively; 20,922,428 and 1,431,615 shares issued and outstanding at December 31, 2016 and 2015 respectively	2
Additional paid-in capital	200,709	440
Accumulated other comprehensive income (loss)	(39)	(45)
Accumulated deficit	(67,871)	(31,496)
Total stockholders' equity (deficit)	132,801	(31,101)
Total liabilities, convertible preferred stock and stockholders' equity (deficit)	$ 140,150	$ 98,459

CONDENSED BALANCE SHEETS (Paren

CONDENSED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
CONDENSED BALANCE SHEETS
Convertible preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Convertible preferred stock, shares authorized	0	14,274,741
Convertible preferred stock, shares issued	0	14,274,741
Convertible preferred stock, shares outstanding	0	14,274,741
Convertible preferred stock, liquidation preference (in dollars)		$ 108,500
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	0
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	290,000,000	20,000,000
Common stock, shares issued	20,922,428	1,431,615
Common stock, shares outstanding	20,922,428	1,431,615

CONDENSED STATEMENTS OF OPERATI

CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	11 Months Ended	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2016	Dec. 31, 2015
Operating expenses:
Research and development	$ 38	$ 29,356	$ 11,352
General and administrative	123	7,620	2,418
Total operating expenses	161	36,976	13,770
Loss from operations	(161)	(36,976)	(13,770)
Change in fair value of convertible preferred stock liability			(17,600)
Interest income and other expense, net		601	35
Net loss	$ (161)	$ (36,375)	$ (31,335)
Net loss per share, basic and diluted (in dollars per share)	$ (0.95)	$ (2.36)	$ (83.86)
Shares used to compute net loss per share, basic and diluted (in shares)	170,278	15,422,041	373,643
Other comprehensive income (loss):
Unrealized gain (loss) on marketable securities		$ 6	$ (45)
Comprehensive loss	$ (161)	$ (36,369)	$ (31,380)

Statements of Changes in Conver

Statements of Changes in Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($) $ in Thousands	IPOCommon Stock	IPOAdditional Paid-In Capital	IPO	Convertible Preferred Stock.	Series A convertible preferred stock	Series B convertible preferred stock	Series A and Series B convertible preferred stock	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Income	Accumulated Deficit	Total
Balance (in shares) at Dec. 31, 2014				3,395,468				1,046,749
Increase (Decrease) in Shares
Issuance of common stock to founders, net of repurchase (in shares)								384,866
Issuance of stock (in shares)					5,525,961	5,353,312
Balance (in shares) at Dec. 31, 2015				14,274,741				1,431,615
Increase (Decrease) in Convertible Preferred Stock
Issuance of convertible preferred stock					$ 20,730	$ 74,839
Reclassification of convertible preferred stock liability				$ 20,200
Balance at Dec. 31, 2015				125,780	$ 50,941	$ 74,839						$ 125,780
Balance at Dec. 31, 2014				$ 10,011					$ 2		$ (161)	(159)
Increase (Decrease) in Stockholders' Deficit
Issuance of common stock for cash upon early exercise of stock options and lapse of restrictions									10			10
Stock-based compensation expense									428			428
Unrealized loss on marketable securities										$ (45)		(45)
Net loss											(31,335)	(31,335)
Balance at Dec. 31, 2015									440	(45)	(31,496)	(31,101)
Increase (Decrease) in Shares
Number of common stock issued with the conversion of the preferred stock (in shares)							(14,274,741)	14,274,741
Issuance of stock (in shares)	5,202,618
Issuance of common stock on exercise of stock options (in shares)								13,454
Balance (in shares) at Dec. 31, 2016								20,922,428
Increase (Decrease) in Stockholders' Deficit
Conversion of convertible preferred stock into common stock							$ (125,780)	$ 1	125,779			125,780
Issuance of common stock	$ 1	$ 70,624	$ 70,625
Common stock issued on exercise of stock options									4			4
Vesting of restricted stocks issued upon early exercise of stock options									34			34
Stock-based compensation expense									3,828			3,828
Unrealized loss on marketable securities										6		6
Net loss											(36,375)	(36,375)
Balance at Dec. 31, 2016								$ 2	$ 200,709	$ (39)	$ (67,871)	$ 132,801

Statements of Changes in Conve6

Statements of Changes in Convertible Preferred Stock and Stockholders' Deficit (Parenthetical) - USD ($) $ in Thousands	11 Months Ended	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2016	Dec. 31, 2015
Convertible preferred stock liability	$ 2,600
Common Stock, issuance costs		$ 7,414
Series A convertible preferred stock
Convertible preferred stock, issuance costs	139		$ 20
Convertible preferred stock liability	$ 2,600
Series B convertible preferred stock
Convertible preferred stock, issuance costs			$ 161

CONDENSED STATEMENTS OF CASH FL

CONDENSED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	11 Months Ended	12 Months Ended
CONDENSED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	Dec. 31, 2014	Dec. 31, 2016	Dec. 31, 2015
Cash flows from operating activities
Net loss	$ (161)	$ (36,375)	$ (31,335)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation		594	148
Amortization/accretion related to marketable securities		648	(41)
Stock-based compensation		3,828	428
Change in fair value of convertible preferred stock liability			17,600
Other			40
Changes in operating assets and liabilities:
Prepaid and other current assets	(12)	290	(1,265)
Other assets		(869)
Accounts payable	57	518	1,240
Accrued and other liabilities	17	2,814	1,218
Other long-term liabilities	3	695	639
Net cash used in operating activities	(96)	(27,857)	(11,328)
Cash flows from investing activities
Purchases of marketable securities		(258,281)	(104,385)
Sales of marketable securities		4,199
Maturities of marketable securities		213,725	14,100
Purchase of property and equipment		(2,199)	(1,747)
Net cash used in investing activities		(42,556)	(92,032)
Cash flows from financing activities
Proceeds from issuance of common stock in IPO, net of issuance costs	2	71,354
Proceeds from issuance of convertible preferred stock, net of issuance costs	12,611		95,569
Payment of offering costs			(729)
Proceeds from exercise of common stock options		4	108
Net cash provided by financing activities	12,613	71,358	94,948
Net increase in cash and cash equivalents	12,517	945	(8,412)
Cash and cash equivalents at beginning of the period		4,105	12,517
Cash and cash equivalents at end of the period	12,517	5,050	4,105
Supplemental disclosures of cash flow information
Convertible preferred stock issuance costs incurred but not paid	36
Purchases of property and equipment incurred but not paid		$ 84	286
Convertible preferred stock liability	$ 2,600
Deferred offering costs incurred but not paid			$ 222

Organization

Organization	12 Months Ended
Organization	Dec. 31, 2016
Organization
Organization	1. Organization Corvus Pharmaceuticals, Inc. ("Corvus" or the "Company") was incorporated in Delaware on January 27, 2014 and commenced operations in November 2014. Corvus is a clinical stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. The Company's primary activities have been establishing its facilities, recruiting personnel, conducting research and development of its product candidates, including conducting a clinical trial, and raising capital. The Company's operations are located in Burlingame, California. The Company has four insignificant subsidiaries.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
Summary of Significant Accounting Policies	Dec. 31, 2016
Summary of Significant Accounting Policies
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America ("U.S. GAAP"). The Company's functional and reporting currency is the U.S. dollar. The accompanying consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and discharge of liabilities in the normal course of business. Since its inception, the Company has incurred significant losses and negative cash flows from operations. As of December 31, 2016, the Company had an accumulated deficit of $67.9 million and cash, cash equivalents and marketable securities of $134.9 million. The Company has financed its operations primarily with the proceeds from the sale of stock. The Company will need to raise additional capital to meet its business objectives. The Company believes that its current cash, cash equivalents and marketable securities will be sufficient to fund its planned expenditures and meet its obligations through at least the next twelve months. Use of Estimates The preparation of the Company's consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from such estimates. Initial Public Offering On March 22, 2016, the Company's registration statement on Form S-1 (File No. 333-208850) relating to its initial public offering ("IPO") of its common stock was declared effective by the Securities and Exchange Commission ("SEC") and the shares of its common stock began trading on the NASDAQ Global Market on March 23, 2016. The public offering price of the shares sold in the IPO was $15.00 per share. The IPO closed on March 29, 2016, pursuant to which the Company sold 4,700,000 shares of its common stock. On April 26, 2016, the Company sold an additional 502,618 shares of its common stock to the underwriters upon partial exercise of their over-allotment option, at the initial offering price of $15.00 per share. The Company received aggregate net proceeds of approximately $70.6 million, after underwriting discounts, commissions and offering expenses. Immediately prior to the consummation of the IPO, all outstanding shares of convertible preferred stock were converted into common stocks. Concentrations of Credit Risk and Other Risks and Uncertainties Substantially all of the Company's cash and cash equivalents are deposited in accounts with two financial institutions that management believes are of high credit quality. Such deposits may, at times, exceed federally insured limits. The Company maintains its cash with an accredited financial institution and accordingly, such funds are subject to minimal credit risk. The Company's marketable securities are direct obligations of the United States government. The Company has not experienced any losses on its deposits of cash, cash equivalents or marketable securities. Since inception, the Company has recurring net losses and negative cash flows from operations. During the year ended December 31, 2016, the Company incurred a net loss of $36.4 million and used $27.9 million of cash in operations. At December 31, 2016, the Company had an accumulated deficit of $67.9 million and does not expect to experience positive cash flows from operations in the near future. The Company has financed operations to date primarily through private placements of convertible preferred stock and proceeds from its IPO. As of December 31, 2016, the Company had cash, cash equivalents and marketable securities of $134.9 million. The Company is subject to a number of risks similar to other early stage biopharmaceutical companies, including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, its reliance on third parties to conduct its clinical trials, the need to obtain marketing approval for its product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of the Company's product candidates, its right to develop and commercialize its product candidates pursuant to the terms and conditions of the licenses granted to the Company, and protection of proprietary technology. If the Company does not successfully commercialize or partner any of its product candidates, it will be unable to generate product revenue or achieve profitability. Segments Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment, that of the development of and commercialization of novel immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. Cash and Cash Equivalents and Marketable Securities The Company considers all highly liquid investment securities with remaining maturities at the date of purchase of three months or less to be cash equivalents. Investments with remaining maturities, at the date of purchase, greater than three months, but less than one year are considered short-term. The Company determines the appropriate classification of marketable securities at the time of purchase and evaluates such designation as of each balance sheet date. To date, all marketable securities have been classified as available-for-sale and are carried at fair value with unrealized gains and losses, if any, included as a component of accumulated other comprehensive income (loss) in stockholders' equity (deficit). Interest and realized gains and losses are included in interest income. Realized gains and losses are recognized based on the specific identification method. Fair Value Measurements Fair value accounting is applied for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the consolidated financial statements on a recurring basis (at least annually). The carrying amount of the Company's financial instruments, including cash equivalents, accounts payable and accrued liabilities, approximate fair value due to their short-term maturities. Deferred Offering Costs Deferred offering costs consist primarily of direct incremental costs related to the Company's initial public offering of its common stock. Upon completion of the initial public offering in March 2016, these amounts were offset against the proceeds of the offering. Property and Equipment, Net Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful lives of the respective assets: Laboratory equipment 5 years Computer equipment and purchased software 3 years Leasehold improvements Shorter of asset's useful life or remaining term of lease Maintenance and repairs that do not extend the life or improve the asset are expensed when incurred. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in operations. Impairment of Long-Lived Assets The Company regularly reviews the carrying value and estimated lives of all of its long-lived assets, including property and equipment, to determine whether indicators of impairment may exist which warrant adjustments to carrying values or estimated useful lives. The determinants used for this evaluation include management's estimate of the asset's ability to generate positive income from operations and positive cash flow in future periods as well as the strategic significance of the assets to the Company's business objectives. Should impairment exist, the impairment loss to be recognized is measured by the amount by which the carrying amount of the asset exceeds the projected discounted future net cash flows arising from the asset. All long-lived assets are maintained in the United States of America. Consolidation The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. Intercompany balances and transactions have been eliminated in consolidation Convertible Preferred Stock Liability The Company determined that the Company's obligation to issue additional shares of the Company's convertible preferred stock represented a freestanding financial instrument, which was accounted for as a liability. The freestanding convertible preferred stock liability was initially recorded at fair value, with fair value changes recognized in the statements of operations and comprehensive loss. The Company estimated the fair value of this liability using an option-pricing model that included assumptions for future financings, expected volatility, expected life and risk-free interest rate. At the time of the exercise of the option (June 2015), the remaining value of the convertible preferred stock liability was reclassified to convertible preferred stock with no further remeasurement required. Research and Development Expenses The Company records research and development expenses as incurred. The Company accounts for nonrefundable advance payments for goods and services that will be used in future research and development activities as expenses when the goods have been received or when the service has been performed rather than when the payment is made. Research and development expenses consist of costs incurred by the Company for the discovery and development of the Company's product candidates and include: • employee-related expenses, including salaries, benefits, travel and non-cash stock-based compensation expense; • external research and development expenses incurred under arrangements with third parties, such as contract research organizations, contract manufacturing organizations, academic and non-profit institutions and consultants; • costs to acquire technologies to be used in research and development that have not reached technological feasibility and have no alternative future use; • license fees; and • other expenses, which include direct and allocated expenses for laboratory, facilities and other costs. Clinical Trial Accruals Costs for preclinical studies and clinical trial activities are recognized based on an evaluation of the vendors' progress towards completion of specific tasks, using data such as clinical site activations, patient enrollment or information provided to the Company by its vendors regarding their actual costs incurred. Payments for these activities are based on the terms of individual contracts and payment timing may differ significantly from the period in which the services are performed. The Company determines accrual estimates through reports from and discussions with applicable personnel and outside service providers as to the progress or state of completion, or the services completed. The Company's estimates of accrued expenses as of each balance sheet date are based on the facts and circumstances known at the time. Stock-Based Compensation The Company maintains incentive plans under which incentive stock options and nonqualified stock options may be granted to employees and non-employee service providers. The Company accounts for stock-based employee compensation arrangements in accordance with the provisions of ASC 718, "Compensation—Stock Compensation." For stock options granted to employees, the Company recognizes compensation expense for all stock-based awards based on the grant-date estimated fair values. The value of the award is recognized as an expense ratably over the requisite service period. The fair value of stock options is determined using the Black-Scholes option pricing model. Forfeitures are accounted for when they occur. Stock-based compensation expense related to stock options granted to non-employees is recognized based on the fair value of the stock options, determined using the Black-Scholes option pricing model. The expense for options granted to non-employees is periodically re-measured as the underlying options vest. The awards generally vest over the time period the Company expects to receive service from the non-employee. Income Taxes The Company accounts for income taxes under the asset and liability method. The Company estimates actual current tax exposure together with assessing temporary differences resulting from differences in accounting for reporting purposes and tax purposes for certain items, such as accruals and allowances not currently deductible for tax purposes. These temporary differences result in deferred tax assets and liabilities, which are included in the Company's balance sheets. In general, deferred tax assets represent future tax benefits to be received when certain expenses previously recognized in the Company's statements of operations and comprehensive loss become deductible expenses, under applicable income tax laws or when net operating loss or credit carryforwards are utilized. Accordingly, realization of the Company's deferred tax assets is dependent on future taxable income against which these deductions, losses and credits can be utilized. The Company must assess the likelihood that the Company's deferred tax assets will be recovered from future taxable income and a valuation allowance is recorded when it is more likely than not that the deferred tax asset will not be recovered. The Company applies judgment in the determination of the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Based on the available evidence, the Company is unable, at this time, to support the determination that it is more likely than not that its deferred tax assets will be utilized in the future. Accordingly, the Company recorded a full valuation allowance for all periods presented. The Company intends to maintain a valuation allowance until sufficient evidence exists to support its reversal. The Company recognizes any material interest and penalties related to unrecognized tax benefits in income tax expense. The Company recognizes benefits of uncertain tax positions if it is more likely than not such positions will be sustained upon examination based solely on their technical merits as the largest amount of benefit that is more likely than not to be realized upon the ultimate settlement. The Company is required to file income tax returns in the U.S. federal jurisdiction. The Company currently is not under examination by the Internal Revenue Service or other jurisdictions for any tax years. Comprehensive Loss Comprehensive loss includes net loss as well as other changes in stockholders' equity (deficit) that result from transactions and economic events other than those with stockholders. The Company's only element of other comprehensive loss in any period presented was unrealized gains and losses on available for sale marketable securities. Net Loss per Share Basic net loss per share is calculated by dividing the net loss by the weighted average number of common shares outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted average number of common shares and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, the convertible preferred stock, common stock subject to repurchase, and stock options are considered to be potentially dilutive securities. Because the Company has reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for those periods. Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2014-09, Revenue from Contracts with Customers, which required an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU No. 2014-09 will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The new standard is effective January 1, 2018 for public companies. Early application is permitted as of January 1, 2017. The standard permits the use of either the retrospective or cumulative effect transition method. In March 2016, the FASB issued ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net), which clarifies the implementation guidance on principal versus agent considerations in ASU No. 2014-09. In April 2016, the FASB issued ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing, which clarifies certain aspects of identifying performance obligations and licensing implementation guidance. In May 2016, the FASB issued ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients, which relates to disclosures of remaining performance obligations, as well as other amendments to guidance on collectability, non-cash consideration and the presentation of sales and other similar taxes collected from customers. These standards have the same effective date and transition date of January 1, 2018. The Company does not believe adopting this guidance will have a material impact on its consolidated financial statements as the Company is not yet generating revenues. In August 2014, the FASB issued ASU No. 2014-15, Disclosure of Uncertainties About an Entity's Ability to Continue as a Going Concern. This standard update provides guidance around management's responsibility to evaluate whether there is substantial doubt about an entity's ability to continue as a going concern and to provide related footnote disclosures. The new guidance is effective for all annual and interim periods ending after December 15, 2016. The Company has adopted ASU 2014-15 as of the year ended December 31, 2016. In November 2015, the FASB issued ASU No 2015-17, Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes. This standard amends the accounting for income taxes and requires all deferred tax assets and liabilities to be classified as non-current on the balance sheet. The new standard is effective for reporting periods beginning after December 15, 2016, with early adoption permitted. The standard may be adopted either prospectively or retrospectively. The Company has adopted ASU 2015-17 as of the year ended December 31, 2016. There was no impact on the consolidated financial statements. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) that replaces existing lease guidance. The new standard requires lessees to record right-of-use assets and corresponding lease liabilities on the balance sheet. The new guidance will continue to classify leases as either finance or operating, with classification affecting the pattern of expense recognition in the statement of income. The standard is effective for the Company beginning June 1, 2019, with early application permitted. The new standard is required to be applied with a modified retrospective approach to each prior reporting period presented with various optional practical expedients. The Company is currently assessing the impact of this guidance on its consolidated financial statements. In March 2016, the FASB issued ASU No. 2016-09, Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The updated guidance changes how companies account for certain aspects of share-based payment awards to employees, including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. The update to the standard is effective for the Company beginning January 1, 2017, with early application permitted. The Company has adopted the provisions of this standard on January 1, 2016, the impact of which on its consolidated financial statements was not significant.

Net Loss per Share

Net Loss per Share	12 Months Ended
Net Loss per Share	Dec. 31, 2016
Net Loss per Share
Net Loss per Share	3. Net Loss per Share The following table shows the calculation of net loss per share (in thousands, except share and per share data): Year Ended Year Ended Period from Numerator: Net loss—basic and diluted $ ) $ ) $ ) Denominator: Weighted average common shares outstanding Less: weighted average common shares subject to repurchase ) ) ) Weighted average common shares outstanding used to compute basic and diluted net loss per share Net loss per share, basic and diluted $ ) $ ) $ ) The amounts in the table below were excluded from the calculation of diluted net loss per share, due to their anti-dilutive effects: Year Ended Year Ended Period from Convertible preferrd stock — Common stock subject to repurchase Outstanding options Total shares of common stock equivalents

Fair Value Measurements

Fair Value Measurements	12 Months Ended
Fair Value Measurements	Dec. 31, 2016
Fair Value Measurements
Fair Value Measurements	4. Fair Value Measurements Financial assets and liabilities are measured and recorded at fair value. The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. The fair value hierarchy prioritizes valuation inputs based on the observable nature of those inputs. The fair value hierarchy applies only to the valuation inputs used in determining the reported fair value of the investments and is not a measure of the investment credit quality. The hierarchy defines three levels of valuation inputs: • Level 1—Quoted prices in active markets for identical assets or liabilities • Level 2—Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly • Level 3—Unobservable inputs that reflect the Company's own assumptions about the assumptions market participants would use in pricing the asset or liability There have been no transfers of assets and liabilities between levels of hierarchy. The following tables present information as of December 31, 2016 and 2015 about the Company's assets that are measured at fair value on a recurring basis and indicate the level of the fair value hierarchy the Company utilized to determine such fair values (in thousands): December 31, 2016 Fair Value Measured Using Total (Level 1) (Level 2) (Level 3) Assets Cash equivalents $ $ — $ — $ Marketable securities — — $ $ — $ — $ December 31, 2015 Fair Value Measured Using Total (Level 1) (Level 2) (Level 3) Assets Cash equivalents $ $ — $ — $ Marketable securities — — $ $ — $ — $ The Company's marketable securities are invested in direct obligations of the United States government for all periods. As of December 31, 2016, marketable securities had a maximum remaining maturity of nine months and consisted of U.S. Treasury securities. The following table presents the issuances, changes in fair value, exercise and reclassification of the Company's Level 3 financial instrument which is measured at fair value on a recurring basis (in thousands): Convertible Balance as of December 31, 2014 $ Change in fair value of convertible preferred stock liability through date of Series A second tranche issuance Recognition of fair value upon issuance of second tranche Series A convertible preferred stock ) Balance as of December 31, 2015 $ — As of December 31, 2016 and 2015, the fair value of available for sale marketable securities by type of security were as follows (in thousands): December 31, 2016 Amortized Gross Gross Fair U.S. Treasury securities $ $ — $ ) $ December 31, 2015 Amortized Gross Gross Fair U.S. Treasury securities $ $ — $ ) $

License and Collaboration Agree

License and Collaboration Agreements	12 Months Ended
License and Collaboration Agreements	Dec. 31, 2016
License and Collaboration Agreements
License and Collaboration Agreements	5. License and Collaboration Agreements Scripps Licensing Agreement In December 2014, the Company entered into a license agreement with The Scripps Research Institute ("Scripps"), pursuant to which it was granted a non-exclusive, world-wide license for all fields of use under Scripps' rights in certain know-how and technology related to a mouse hybridoma clone expressing an anti-human CD73 antibody, and to progeny, mutants or unmodified derivatives of such hybridoma and any antibodies expressed by such hybridoma. Scripps also granted the Company the right to grant sublicenses in conjunction with other proprietary rights the Company holds, or to others collaborating with or performing services for the Company. Under this license agreement, Scripps has agreed not to grant any additional commercial licenses with respect to such materials, other than march-in rights granted to the U.S. government. Upon execution of the agreement, the Company made a one-time cash payment to Scripps of $10,000 in 2015 and is also obligated to pay a minimum annual fee to Scripps of $25,000. The one-time cash payment was recorded as research and development expense as technological feasibility of the asset had not been established and there was no alternative future use. The first minimum annual fee payment is due on the first anniversary of effective date of the agreement and will be due on each subsequent anniversary of the effective date for the term of the agreement. The Company is also required to make performance-based cash payments upon successful completion of clinical and sales milestones. The aggregate potential milestone payments are $2.6 million. The Company is also required to pay royalties on net sales of licensed products sold by it, its affiliates and its sublicensees at a rate in the low-single digits. In addition, should the Company sublicense the rights licensed under the agreement, it has agreed to pay a percentage of sublicense revenue received at specified rates that start at double digit percentages and decrease to single digit percentages based on the elapsed time from the effective date of the agreement and the time of entry into such sublicense. To date, no milestone payments have been made. The Company's license agreement with Scripps will terminate upon expiration of its obligation to pay royalties to Scripps under the license agreement. The Company's license agreement with Scripps is terminable by the consent of the parties, at will by the Company upon providing 90 days written notice to Scripps, or by Scripps for certain material breaches, or if the Company undergoes a bankruptcy event. In addition, Scripps may terminate the license on a product-by-product basis, or the entire agreement, if the Company fails to meet specified diligence obligations related to the development and commercialization of licensed products. Scripps may also terminate the agreement after the third anniversary of the effective date of the agreement if it reasonably believes, based on reports the Company provides to Scripps, that the Company has not used commercially reasonable efforts as required under the agreement, subject to a specified notice and cure period. Vernalis Licensing Agreement In February 2015, the Company entered into a license agreement with Vernalis (R&D) Limited ("Vernalis"), which was subsequently amended as of November 5, 2015, and, pursuant to which the Company was granted an exclusive, worldwide license under certain patent rights and know-how, including a limited right to grant sublicenses, for all fields of use to develop, manufacture and commercialize products containing certain adenosine receptor antagonists, including CPI-444. Pursuant to this agreement, the Company made a one-time cash payment to Vernalis in the amount of $1.0 million, which was recorded as research and development expense as technological feasibility of the asset had not been established and there was no alternative future use. The Company is also required to make cash milestone payments to Vernalis upon the successful completion of clinical and regulatory milestones for licensed products depending on the indications for which such licensed products are developed and upon achievement of certain sales milestones. On February 13, 2017, the Company made a milestone payment of $3.0 million to Vernalis following the expansion of a cohort of patients with renal cell cancer treated with single agent CPI-444 in the Company's Phase 1/1b clinical trial. The aggregate potential milestone payments exceed $200 million for all indications. The Company has also agreed to pay Vernalis tiered incremental royalties based on the annual net sales of licensed products containing CPI-444 on a product-by-product and country-by-country basis, subject to certain offsets and reductions. The tiered royalty rates for products containing CPI-444 range from the mid-single digits up to the low-double digits on a country-by-country net sales basis. The royalties on other licensed products that do not include CPI-444 also increase with the amount of net sales on a product-by-product and country-by-country basis and range from the low-single digits up to the mid-single digits on a country-by-country net sales basis. The Company is also obligated to pay to Vernalis certain sales milestones as indicated above when worldwide net sales reach specified levels over an agreed upon time period. The agreement will expire on a product-by-product and country-by-country basis upon the expiration of the Company's payment obligations to Vernalis in respect of a particular product and country. Both parties have the right to terminate the agreement for an uncured material breach by the other party. The Company may also terminate the agreement at its convenience by providing 90 days written notice, provided that the Company has not received notice of its own default under the agreement at the time the Company exercises such termination right. Vernalis may also terminate the agreement if the Company challenges a licensed patent or undergoes a bankruptcy event. Genentech Collaboration Agreement In October 2015, the Company entered into a clinical trial collaboration agreement with Genentech to evaluate the safety, tolerability and preliminary efficacy of CPI-444 combined with Genentech's investigational cancer immunotherapy, Tecentriq (atezolizumab), a fully humanized monoclonal antibody targeting protein programmed cell death ligand 1("PD-L1"), in a variety of solid tumors in a Phase 1/1b clinical trial. Pursuant to this agreement, the Company will be responsible for the conduct and cost of the relevant studies, under the supervision of a joint development committee made up of representatives of the Company and representatives of Genentech. Genentech will supply Tecentriq. As part of the agreement, the Company granted Genentech certain rights of first negotiation to participate in future clinical trials that the Company may conduct evaluating the administration of CPI-444 in combination with an anti-PD-1 or anti-PD-L1 antibody. If the Company and Genentech do not reach agreement on the terms of any such participation by Genentech within a specified time period, the Company retains the right to collaborate with third parties in such activities. The Company also granted Genentech certain rights of first negotiation should it decide to license development and commercialization rights to CPI-444. Should the Company and Genentech not reach agreement on the terms of such a license within a specified time period, it retains the right to enter into a license with another third party. The Company and Genentech each have the right to terminate the agreement for material breach by the other party. In addition, the agreement may be terminated by either party due to safety considerations, if directed by a regulatory authority or if development of CPI-444 or Tecentriq is discontinued. Further, the agreement will expire after a set period of time following the provision by the Company of the final clinical study report to Genentech.

Balance Sheet Components

Balance Sheet Components	12 Months Ended
Balance Sheet Components	Dec. 31, 2016
Balance Sheet Components
Balance Sheet Components	6. Balance Sheet Components (in thousands): December 31, December 31, Prepaid and Other Current Assets Interest receivable $ $ — Prepaid research and development manufacturing expenses — Tenant improvement allowance receivable — Other $ $ Property and Equipment, net Laboratory equipment $ $ Computer equipment and purchased software Leasehold improvements Construction in progress — Less: accumulated depreciation and amortization ) ) $ $ Accrued and Other Liabilities Accrued clinical trial related $ $ Accrued manufacturing expense Personnel related Deferred rent Accrued legal and accounting Accrued contruction in progress costs — Other accrued expenses $ $ Other Liabilities Deferred rent $ $ Shares subject to vesting $ $

Convertible Preferred Stock

Convertible Preferred Stock	12 Months Ended
Convertible Preferred Stock	Dec. 31, 2016
Convertible Preferred Stock
Convertible Preferred Stock	7. Convertible Preferred Stock Under the amended and restated certificate of incorporation in effect as of December 31, 2016, the Company is authorized to issue two classes of stock: preferred stock and common stock. Immediately prior to the consummation of the IPO on March 29, 2016, all outstanding shares of Series A and B convertible preferred stock were converted into 14,274,741 shares of common stock on a one-for-one basis. As such, no convertible preferred stock shares were outstanding as of December 31, 2016. Convertible preferred stock as of December 31, 2015 consisted of the following (in thousands, except share data): Shares Shares Net Liquidation Series A $ $ Series B Total $ $

Convertible Preferred Stock Lia

Convertible Preferred Stock Liability	12 Months Ended
Convertible Preferred Stock Liability	Dec. 31, 2016
Convertible Preferred Stock Liability
Convertible Preferred Stock Liability	8. Convertible Preferred Stock Liability On November 26, 2014, the Company executed the Series A Convertible Preferred Stock Purchase Agreement for the issuance of up to 8,921,438 shares of Series A convertible preferred stock and issued 3,395,468 shares for net proceeds of $12.6 million in connection with the first closing of the first tranche. In January 2015, in connection with the second closing of the first tranche, the Company issued 1,065,246 shares of Series A convertible preferred stock for net proceeds of $4.0 million and in June 2015, in connection with the closing of the second tranche, an additional 4,460,715 shares of Series A convertible preferred stock were issued for net proceeds of $16.7 million. The Series A Convertible Preferred Stock Purchase Agreement provided that, upon the earliest to occur of any of three defined triggers, each investor of the first tranche agreed to purchase its pro-rata portion of the shares to be issued in the second tranche and the Company agreed to sell and issue said shares of Series A convertible preferred stock on the same terms as the first tranche. A convertible preferred stock liability was recorded for the Company's obligation to sell the second tranche of the Series A convertible preferred stock to the first tranche stockholders at a fixed price of $3.755 per share upon the satisfaction of certain conditions. A liability was initially recorded in connection with the first tranche of the Series A convertible preferred stock financing at its initial estimated fair value of $2.6 million, with gains and losses arising from changes in fair value recognized in the statements of operations at each period while such instrument was classified as a liability. A $17.6 million charge was recorded for the change in estimated fair value of the Series A convertible preferred stock liability for the period from January 1, 2015 to the closing of the second tranche in June 2015. Upon the closing of the second tranche in June 2015, the liability terminated and the balance of the liability of $20.2 million was reclassified to convertible preferred stock. The preferred stock liability related to Series A convertible preferred stock was valued at issuance and at December 31, 2014 and March 31, 2015 using a black scholes option-pricing method based on the consideration paid for the Series A convertible preferred stock and the convertible preferred stock liability using an assumed term of 1.0 years and 0.75 years, an interest rate of 0.13% and 0.20% and a volatility of 85% and 85%, respectively. Immediately prior to its exercise on June 10, 2015, the convertible preferred stock liability's fair value was estimated based on its intrinsic value, with the fair value of the Series A convertible preferred stock estimated as of June 10, 2015 and compared to the exercise price of the Series A convertible preferred stock liability. To estimate the fair value of the Series A convertible preferred stock as of June 10, 2015, the enterprise value of the Company was estimated based on potential IPO and sale estimates. The enterprise value was then allocated to the various classes of securities using an option pricing model that assumed a term of two years to a liquidity event, an interest rate of 0.75% and a volatility of 75% based on market conditions and expectations as of the June valuation date.

Common Stock

Common Stock	12 Months Ended
Common Stock	Dec. 31, 2016
Common Stock.
Common Stock	9. Common Stock As of December 31, 2016, the amended and restated certificate of incorporation authorizes the Company to issue 290 million shares of common stock and 10 million shares of preferred stock. Each share of common stock is entitled to one vote. Common stockholders are entitled to dividends if and when declared by the board of directors. As of December 31, 2016, no dividends on common stock had been declared. The Company reserved shares of common stock on an as-converted basis, for issuance as follows: December 31, December 31, December 31, Convertible preferred stock — Shares available for future option grants Outstanding options Unvested restricted common stock (founders and early exercise of stock options) Shares reserved for employee stock purchase plan — — Total

Stock Option Plans

Stock Option Plans	12 Months Ended
Stock Option Plans	Dec. 31, 2016
Stock Option Plans
Stock Option Plans	10. Stock Option Plans In February 2014, the Company adopted the 2014 Equity Incentive Plan (the "2014 Plan"), which was subsequently amended in November 2014, July 2015 and September 2015, under which it granted incentive stock options ("ISOs") or non-qualified stock options ("NSOs"). Terms of stock agreements, including vesting requirements, are determined by the board of directors or a committee authorized by the board of directors, subject to the provisions of the 2014 Plan. In general, awards granted by the Company vest over four years and have maximum exercise term of 10 years. The 2014 Plan provides that grants must be at an exercise price of 100% of fair market value of the Company's common stock as determined by the board of directors on the date of the grant. In connection with the consummation of the IPO in March 2016, the 2016 Equity Incentive Award Plan (the "2016 Plan"), became effective. Under the 2016 Plan, incentive stock options, non-statutory stock options, stock purchase rights and other stock-based awards may be granted. Terms of stock agreements, including vesting requirements, are determined by the board of directors or a committee authorized by the board of directors, subject to the provisions of the 2016 Plan. In general, awards granted by the Company vest over four years and have maximum exercise term of 10 years. The 2016 Plan provides that grants must be at an exercise price of 100% of fair market value of the Company's common stock as determined by the board of directors on the date of the grant. In conjunction with adopting the 2016 Plan, the 2014 Plan was terminated and no further awards will be granted under the 2014 Plan. Options outstanding under the 2014 Plan as of the effective date of the 2016 Plan that are forfeited or lapse unexercised may be re-issued under the 2016 Plan, up to a maximum of 1,136,229 shares. Activity under the Company's stock option plans is set forth below: Options Outstanding Shares Number Weighted- Balance at December 31, 2015 $ Additional shares authorized Options granted ) Options exercised — ) Options forfeited ) Balance at December 31, 2016 $ The following table summarizes information about stock options outstanding at December 31, 2016 and 2015: Options Outstanding Options Vested Exercise Price Number Weighted Weighted Number Weighted Weighted $0.28 $ $ $4.65 $ $ $6.75 $ $ $13.34 - 16.37 $ $ $ $ Options Outstanding Options Vested Exercise Price Number Weighted Weighted Number Weighted Weighted $0.28 - $4.65 $ $ $6.75 - $15.79 $ — $ $ The weighted average grant date fair value of options granted for the year ended December 31, 2016, 2015 and for the period January 27, 2014 (inception) through December 31, 2014, was $10.78, $4.37 and $0.22, respectively. Options outstanding and exercisable that had vested or were expected to vest at December 31, 2016 were as follows: Number of shares Weighted Weighted Aggregate Vested $ $ Expected to vest $ $ In the table above, aggregate intrinsic value represents the difference between the exercise price of the options to purchase common stock and the estimated fair value of the Company's common stock of $14.30. The aggregate intrinsic value of stock options exercised in the year ended December 31, 2016, 2015 and the period January 27, 2014 (inception) through December 31, 2014, was $216,000, $714,000 and $0, respectively. The total fair value of options that vested in the year ended December 31, 2016, 2015 and the period January 27, 2014 (inception) through December 31, 2014, was $3,195,000, $75,000, and $100, respectively.

Stock-Based Compensation

Stock-Based Compensation	12 Months Ended
Stock-Based Compensation	Dec. 31, 2016
Stock-Based Compensation
Stock-Based Compensation	11. Stock-Based Compensation The Company's results of operations include expenses relating to employee and non-employee stock-based awards as follows (in thousands): Year Ended Year Ended Period from Research and development $ $ $ — General and administrative — Total $ $ $ — Valuation Assumptions The Company estimated the fair value of employee stock options using the Black-Scholes valuation model. The fair value of employee stock options is being amortized on a straight-line basis over the requisite service period of the awards. The fair value of employee stock options were estimated using the following assumptions for the years ended December 31, 2016, 2015 and 2014: Year Ended Year Ended Period from Risk-free interest rate % % % Expected volatility % % % Expected term (in years) Expected divident yield % % % Risk-free Interest Rate: The Company based the risk-free interest rate over the expected term of the options based on the constant maturity rate of U.S. Treasury securities with similar maturities as of the date of the grant. Volatility: The Company used an average historical stock price volatility of comparable public companies within the biotechnology and pharmaceutical industry using an average of historical volatilities of the Company's industry peers. Expected Term: The Company uses the simplified method prescribed in the ASC 718, Compensation—Stock Compensation, to calculate the expected term of options granted to employees and directors. Expected Dividends: The Company has not paid and does not anticipate paying any dividends in the near future. At December 31, 2016 and 2015, the unrecognized compensation expense associated with respect to options granted to employees was $18.5 million and $4.7 million, respectively, and is expected to be recognized on a straight-line basis over 3.28 and 3.64 years, respectively. Stock-based compensation expense related to awards to non-employees is recognized based on the then-current fair value at each measurement date over the associated service period of the award, which is generally the vesting term, on a straight line basis. The Company used the Black-Scholes valuation model to assist it in determining the fair value of stock-based awards. Stock-based compensation expense for non-employees was $142,500 and $42,848 for the years ended December 31, 2016 and 2015, respectively. The following assumptions were used in valuation of non-employee stock options: Year Ended Year Ended Risk-free interest rate 1.90% - 1.94% 1.8% - 2.2% Expected volatility 92.1% - 92.7% 82% - 84.7% Expected term (in years) 8.1 - 8.6 9.1 - 10.0 Expected divident yield 0% 0%

Income Taxes

Income Taxes	12 Months Ended
Income Taxes	Dec. 31, 2016
Income Taxes
Income Taxes	12. Income Taxes During the year ended December 31, 2016, 2015 and 2014, the Company recorded no income tax benefits for the net operating losses (NOLs) incurred due to the uncertainty of realizing a benefit from those items. As of December 31, 2016, the Company had federal NOL carryforwards of approximately $20.0 million and state NOL carryforwards of approximately $45.0 million which are available to reduce future taxable income. The NOLs will begin to expire in 2034, if not utilized. As of December 31, 2016, the Company also had $1.3 million of federal and $1.7 million of state research and development tax credit carryforwards available to reduce future income taxes. The federal research and development tax credits will begin to expire 2035, if not utilized. The state research and development tax credits have no expiration date. Utilization of NOL carryforwards and credits may be subject to an annual limitation due to the ownership change provisions provided by the Internal Revenue Code of 1986, as amended ("Code"), and similar state provisions. An annual limitation may result in the expiration of NOLs and credits before utilization. In March and April 2016, the Company issued a total of 5.2 million shares of common stock associated with its IPO. In addition, during the third quarter of 2015, the Company issued a new series of convertible preferred stock. The common and preferred stock issuances may have created an ownership change under these provisions of the Code and similar state provisions. As of December 31, 2016, NOLs and credits are not expected to expire unused in the carryforward period as a result of these recent issuances of convertible preferred shares. The components of loss before income tax is as follows (in thousands): 2016 2015 2014 Domestic $ ) $ ) $ ) Foreign ) — — $ ) $ ) $ ) A reconciliation of the Company's effective tax rate to the U.S. Federal statutory rate is as follows: December 31, December 31, December 31, Federal tax benefit at statutory rate % % % State tax, net of Federal benefit Loss due to change in fair value of convertible preferred stock liability — ) — Foreign rate differential ) — — Change in valuation allowance ) ) ) Effective income tax rate % % % The effective tax rate is different from the federal statutory tax rate primarily due to a foreign rate differential and a valuation allowance against deferred tax assets as a result of the Company's history of losses. The principal components of the Company's net deferred tax assets are as follows (in thousands) December 31, December 31, Net operating loss carryforwards $ $ Tax credit carryforwards Capitalized tax assets Accruals Stock compensation Other Total deferred tax assets Valuation allowance ) ) Net deferred tax assets $ — $ — The Company recorded a valuation allowance against its deferred tax assets at December 31, 2016 and 2015 because Company management believed that it was more likely than not that these assets would not be fully realized. The valuation allowance increased by approximately $ 7.0 million and $5.8 million for the years ended December 31, 2016 and 2015, respectively. Changes in the valuation allowance for deferred tax assets relate primarily to the increase in the Company's net operating loss carryforward. As of December 31, 2016, the Company had unrecognized tax benefits ("UTBs") of approximately $0.6 million. All of the deferred tax assets associated with these UTBs are fully offset by a valuation allowance. The following table summarizes the activity related to UTBs: December 31, December 31, December 31, Unrecognized tax benefits beginning of the period $ $ — $ — Increase related to the prior year — — Increased related to the current year — Unrecognized tax benefits, end of the period $ $ $ — The Company follows the provisions of ASC 740, Accounting for Income Taxes, and the accounting guidance related to accounting for uncertainty in income taxes. The Company determines its uncertain tax positions based on a determination of whether and how much of a tax benefit taken by the Company in its tax filings or positions is more likely than not to be sustained upon examination by the relevant income tax authorities. The Company will recognize both accrued interest and penalties related to unrecognized benefits in income tax expense. Since the Company is in a loss carryforward position, the Company is generally subject to examination by the U.S. federal, state and local income tax authorities for all tax years in which a loss carryforward is available.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
Commitments and Contingencies	Dec. 31, 2016
Commitments and Contingencies.
Commitments and Contingencies	13. Commitments and Contingencies Facility Lease In January 2015, the Company signed an initial operating lease, effective February 1, 2015 for 8,138 square feet of office and laboratory space with a one-year term. Between January 2015 and August 2016, the Company entered into a series of lease amendments to increase the amount of leased space to 28,633 square feet and extend the expiration of the lease to February 2021. The lease agreement includes an annual rent escalation clause and a right to extend the term at the then current market rate for three years. Under the lease and subsequent amendments, the landlord provided approximately $1.9 million in free rent and lease incentives. The Company records rent expense on a straight-line basis over the effective term of the lease, including any free rent periods and incentives. The lease requires the Company to pay additional amounts for operating and maintenance expenses. Rent expense related to the facilities lease for the years ended years ended December 31, 2016 and 2015 was approximately $584,000 and $347,000, respectively. As of December 31, 2016, future minimum lease payments under the facility lease were as follows (in thousands): Payments Due by Period Total Less than 2 - 3 years 4 - 5 Years More than Contractual obligations: Operating lease obligations $ $ $ $ $ — Total contractual obligations $ $ $ $ $ — In August 2015 the Company entered into an agreement for a line of credit of $0.1 million for the purpose of issuing its landlord a letter of credit of $0.1 million as a security deposit under its facility lease. The Company pledged money market funds and marketable securities as collateral for the line of credit. Pursuant to the Company's license agreements with each of Vernalis and Scripps, it has obligations to make future milestone and royalty payments to these parties, respectively. However, because these amounts are contingent, they have not been included on the Company's balance sheet. Indemnifications In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third-party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. The Company has never incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. The Company has also entered into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers to the fullest extent permitted by Delaware corporate law. There have been no claims to date and the Company has a directors and officers insurance policy that may enable it to recover a portion of any amounts paid for future claims. Legal Proceedings The Company is not a party to any material legal proceedings.

Quarterly Selected Financial Da

Quarterly Selected Financial Data (unaudited)	12 Months Ended
Quarterly Selected Financial Data (unaudited)	Dec. 31, 2016
Quarterly Selected Financial Data (unaudited)
Quarterly Selected Financial Data (unaudited)	14. Quarterly Selected Financial Data (unaudited) Quarter Ended December 31, September 30, June 30, March 31, Operating Expenses $ $ $ $ Net loss ) ) ) ) Net loss per share, basic and diluted $ ) $ ) $ ) $ ) Quarter Ended December 31, September 30, June 30, March 31, Operating Expenses $ $ $ $ Net loss ) ) ) ) Net loss per share, basic and diluted $ ) $ ) $ ) $ )

Subsequent Events

Subsequent Events	12 Months Ended
Subsequent Events	Dec. 31, 2016
Subsequent Events
Subsequent Events	15. Subsequent Events In February 2017, the Company made a $3.0 million milestone payment to Vernalis pursuant to the license agreement entered into in February 2015.

Summary of Significant Accoun23

Summary of Significant Accounting Policies (Policies)	12 Months Ended
Summary of Significant Accounting Policies (Policies)	Dec. 31, 2016
Summary of Significant Accounting Policies
Basis of Presentation	Basis of Presentation The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America ("U.S. GAAP"). The Company's functional and reporting currency is the U.S. dollar. The accompanying consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and discharge of liabilities in the normal course of business. Since its inception, the Company has incurred significant losses and negative cash flows from operations. As of December 31, 2016, the Company had an accumulated deficit of $67.9 million and cash, cash equivalents and marketable securities of $134.9 million. The Company has financed its operations primarily with the proceeds from the sale of stock. The Company will need to raise additional capital to meet its business objectives. The Company believes that its current cash, cash equivalents and marketable securities will be sufficient to fund its planned expenditures and meet its obligations through at least the next twelve months.
Use of Estimates	Use of Estimates The preparation of the Company's consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from such estimates.
Initial Public Offering	Initial Public Offering On March 22, 2016, the Company's registration statement on Form S-1 (File No. 333-208850) relating to its initial public offering ("IPO") of its common stock was declared effective by the Securities and Exchange Commission ("SEC") and the shares of its common stock began trading on the NASDAQ Global Market on March 23, 2016. The public offering price of the shares sold in the IPO was $15.00 per share. The IPO closed on March 29, 2016, pursuant to which the Company sold 4,700,000 shares of its common stock. On April 26, 2016, the Company sold an additional 502,618 shares of its common stock to the underwriters upon partial exercise of their over-allotment option, at the initial offering price of $15.00 per share. The Company received aggregate net proceeds of approximately $70.6 million, after underwriting discounts, commissions and offering expenses. Immediately prior to the consummation of the IPO, all outstanding shares of convertible preferred stock were converted into common stocks.
Concentrations of Credit Risk and Other Risks and Uncertainties	Concentrations of Credit Risk and Other Risks and Uncertainties Substantially all of the Company's cash and cash equivalents are deposited in accounts with two financial institutions that management believes are of high credit quality. Such deposits may, at times, exceed federally insured limits. The Company maintains its cash with an accredited financial institution and accordingly, such funds are subject to minimal credit risk. The Company's marketable securities are direct obligations of the United States government. The Company has not experienced any losses on its deposits of cash, cash equivalents or marketable securities. Since inception, the Company has recurring net losses and negative cash flows from operations. During the year ended December 31, 2016, the Company incurred a net loss of $36.4 million and used $27.9 million of cash in operations. At December 31, 2016, the Company had an accumulated deficit of $67.9 million and does not expect to experience positive cash flows from operations in the near future. The Company has financed operations to date primarily through private placements of convertible preferred stock and proceeds from its IPO. As of December 31, 2016, the Company had cash, cash equivalents and marketable securities of $134.9 million. The Company is subject to a number of risks similar to other early stage biopharmaceutical companies, including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, its reliance on third parties to conduct its clinical trials, the need to obtain marketing approval for its product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of the Company's product candidates, its right to develop and commercialize its product candidates pursuant to the terms and conditions of the licenses granted to the Company, and protection of proprietary technology. If the Company does not successfully commercialize or partner any of its product candidates, it will be unable to generate product revenue or achieve profitability.
Segments	Segments Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment, that of the development of and commercialization of novel immuno-oncology therapies that are designed to harness the immune system to attack cancer cells.
Cash and Cash Equivalents and Marketable Securities	Cash and Cash Equivalents and Marketable Securities The Company considers all highly liquid investment securities with remaining maturities at the date of purchase of three months or less to be cash equivalents. Investments with remaining maturities, at the date of purchase, greater than three months, but less than one year are considered short-term. The Company determines the appropriate classification of marketable securities at the time of purchase and evaluates such designation as of each balance sheet date. To date, all marketable securities have been classified as available-for-sale and are carried at fair value with unrealized gains and losses, if any, included as a component of accumulated other comprehensive income (loss) in stockholders' equity (deficit). Interest and realized gains and losses are included in interest income. Realized gains and losses are recognized based on the specific identification method.
Fair Value Measurements	Fair Value Measurements Fair value accounting is applied for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the consolidated financial statements on a recurring basis (at least annually). The carrying amount of the Company's financial instruments, including cash equivalents, accounts payable and accrued liabilities, approximate fair value due to their short-term maturities.
Deferred Offering Costs	Deferred Offering Costs Deferred offering costs consist primarily of direct incremental costs related to the Company's initial public offering of its common stock. Upon completion of the initial public offering in March 2016, these amounts were offset against the proceeds of the offering.
Property and Equipment, Net	Property and Equipment, Net Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful lives of the respective assets: Laboratory equipment 5 years Computer equipment and purchased software 3 years Leasehold improvements Shorter of asset's useful life or remaining term of lease Maintenance and repairs that do not extend the life or improve the asset are expensed when incurred. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in operations.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company regularly reviews the carrying value and estimated lives of all of its long-lived assets, including property and equipment, to determine whether indicators of impairment may exist which warrant adjustments to carrying values or estimated useful lives. The determinants used for this evaluation include management's estimate of the asset's ability to generate positive income from operations and positive cash flow in future periods as well as the strategic significance of the assets to the Company's business objectives. Should impairment exist, the impairment loss to be recognized is measured by the amount by which the carrying amount of the asset exceeds the projected discounted future net cash flows arising from the asset. All long-lived assets are maintained in the United States of America.
Consolidation	Consolidation The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. Intercompany balances and transactions have been eliminated in consolidation
Convertible Preferred Stock Liability	Convertible Preferred Stock Liability The Company determined that the Company's obligation to issue additional shares of the Company's convertible preferred stock represented a freestanding financial instrument, which was accounted for as a liability. The freestanding convertible preferred stock liability was initially recorded at fair value, with fair value changes recognized in the statements of operations and comprehensive loss. The Company estimated the fair value of this liability using an option-pricing model that included assumptions for future financings, expected volatility, expected life and risk-free interest rate. At the time of the exercise of the option (June 2015), the remaining value of the convertible preferred stock liability was reclassified to convertible preferred stock with no further remeasurement required.
Research and Development Expenses	Research and Development Expenses The Company records research and development expenses as incurred. The Company accounts for nonrefundable advance payments for goods and services that will be used in future research and development activities as expenses when the goods have been received or when the service has been performed rather than when the payment is made. Research and development expenses consist of costs incurred by the Company for the discovery and development of the Company's product candidates and include: • employee-related expenses, including salaries, benefits, travel and non-cash stock-based compensation expense; • external research and development expenses incurred under arrangements with third parties, such as contract research organizations, contract manufacturing organizations, academic and non-profit institutions and consultants; • costs to acquire technologies to be used in research and development that have not reached technological feasibility and have no alternative future use; • license fees; and • other expenses, which include direct and allocated expenses for laboratory, facilities and other costs.
Clinical Trial Accruals	Clinical Trial Accruals Costs for preclinical studies and clinical trial activities are recognized based on an evaluation of the vendors' progress towards completion of specific tasks, using data such as clinical site activations, patient enrollment or information provided to the Company by its vendors regarding their actual costs incurred. Payments for these activities are based on the terms of individual contracts and payment timing may differ significantly from the period in which the services are performed. The Company determines accrual estimates through reports from and discussions with applicable personnel and outside service providers as to the progress or state of completion, or the services completed. The Company's estimates of accrued expenses as of each balance sheet date are based on the facts and circumstances known at the time.
Stock-Based Compensation	Stock-Based Compensation The Company maintains incentive plans under which incentive stock options and nonqualified stock options may be granted to employees and non-employee service providers. The Company accounts for stock-based employee compensation arrangements in accordance with the provisions of ASC 718, "Compensation—Stock Compensation." For stock options granted to employees, the Company recognizes compensation expense for all stock-based awards based on the grant-date estimated fair values. The value of the award is recognized as an expense ratably over the requisite service period. The fair value of stock options is determined using the Black-Scholes option pricing model. Forfeitures are accounted for when they occur. Stock-based compensation expense related to stock options granted to non-employees is recognized based on the fair value of the stock options, determined using the Black-Scholes option pricing model. The expense for options granted to non-employees is periodically re-measured as the underlying options vest. The awards generally vest over the time period the Company expects to receive service from the non-employee.
Income Taxes	Income Taxes The Company accounts for income taxes under the asset and liability method. The Company estimates actual current tax exposure together with assessing temporary differences resulting from differences in accounting for reporting purposes and tax purposes for certain items, such as accruals and allowances not currently deductible for tax purposes. These temporary differences result in deferred tax assets and liabilities, which are included in the Company's balance sheets. In general, deferred tax assets represent future tax benefits to be received when certain expenses previously recognized in the Company's statements of operations and comprehensive loss become deductible expenses, under applicable income tax laws or when net operating loss or credit carryforwards are utilized. Accordingly, realization of the Company's deferred tax assets is dependent on future taxable income against which these deductions, losses and credits can be utilized. The Company must assess the likelihood that the Company's deferred tax assets will be recovered from future taxable income and a valuation allowance is recorded when it is more likely than not that the deferred tax asset will not be recovered. The Company applies judgment in the determination of the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Based on the available evidence, the Company is unable, at this time, to support the determination that it is more likely than not that its deferred tax assets will be utilized in the future. Accordingly, the Company recorded a full valuation allowance for all periods presented. The Company intends to maintain a valuation allowance until sufficient evidence exists to support its reversal. The Company recognizes any material interest and penalties related to unrecognized tax benefits in income tax expense. The Company recognizes benefits of uncertain tax positions if it is more likely than not such positions will be sustained upon examination based solely on their technical merits as the largest amount of benefit that is more likely than not to be realized upon the ultimate settlement. The Company is required to file income tax returns in the U.S. federal jurisdiction. The Company currently is not under examination by the Internal Revenue Service or other jurisdictions for any tax years.
Comprehensive Loss	Comprehensive Loss Comprehensive loss includes net loss as well as other changes in stockholders' equity (deficit) that result from transactions and economic events other than those with stockholders. The Company's only element of other comprehensive loss in any period presented was unrealized gains and losses on available for sale marketable securities.
Net Loss per Share	Net Loss per Share Basic net loss per share is calculated by dividing the net loss by the weighted average number of common shares outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted average number of common shares and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, the convertible preferred stock, common stock subject to repurchase, and stock options are considered to be potentially dilutive securities. Because the Company has reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for those periods.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2014-09, Revenue from Contracts with Customers, which required an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU No. 2014-09 will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The new standard is effective January 1, 2018 for public companies. Early application is permitted as of January 1, 2017. The standard permits the use of either the retrospective or cumulative effect transition method. In March 2016, the FASB issued ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net), which clarifies the implementation guidance on principal versus agent considerations in ASU No. 2014-09. In April 2016, the FASB issued ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing, which clarifies certain aspects of identifying performance obligations and licensing implementation guidance. In May 2016, the FASB issued ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients, which relates to disclosures of remaining performance obligations, as well as other amendments to guidance on collectability, non-cash consideration and the presentation of sales and other similar taxes collected from customers. These standards have the same effective date and transition date of January 1, 2018. The Company does not believe adopting this guidance will have a material impact on its consolidated financial statements as the Company is not yet generating revenues. In August 2014, the FASB issued ASU No. 2014-15, Disclosure of Uncertainties About an Entity's Ability to Continue as a Going Concern. This standard update provides guidance around management's responsibility to evaluate whether there is substantial doubt about an entity's ability to continue as a going concern and to provide related footnote disclosures. The new guidance is effective for all annual and interim periods ending after December 15, 2016. The Company has adopted ASU 2014-15 as of the year ended December 31, 2016. In November 2015, the FASB issued ASU No 2015-17, Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes. This standard amends the accounting for income taxes and requires all deferred tax assets and liabilities to be classified as non-current on the balance sheet. The new standard is effective for reporting periods beginning after December 15, 2016, with early adoption permitted. The standard may be adopted either prospectively or retrospectively. The Company has adopted ASU 2015-17 as of the year ended December 31, 2016. There was no impact on the consolidated financial statements. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) that replaces existing lease guidance. The new standard requires lessees to record right-of-use assets and corresponding lease liabilities on the balance sheet. The new guidance will continue to classify leases as either finance or operating, with classification affecting the pattern of expense recognition in the statement of income. The standard is effective for the Company beginning June 1, 2019, with early application permitted. The new standard is required to be applied with a modified retrospective approach to each prior reporting period presented with various optional practical expedients. The Company is currently assessing the impact of this guidance on its consolidated financial statements. In March 2016, the FASB issued ASU No. 2016-09, Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The updated guidance changes how companies account for certain aspects of share-based payment awards to employees, including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. The update to the standard is effective for the Company beginning January 1, 2017, with early application permitted. The Company has adopted the provisions of this standard on January 1, 2016, the impact of which on its consolidated financial statements was not significant.

Summary of Significant Accoun24

Summary of Significant Accounting Policies (Tables)	12 Months Ended
Summary of Significant Accounting Policies (Tables)	Dec. 31, 2016
Summary of Significant Accounting Policies
Schedule of estimated useful lives of property and equipment, net	Laboratory equipment 5 years Computer equipment and purchased software 3 years Leasehold improvements Shorter of asset's useful life or remaining term of lease

Net Loss per Share (Tables)

Net Loss per Share (Tables)	12 Months Ended
Net Loss per Share (Tables)	Dec. 31, 2016
Net Loss per Share
Schedule of net loss per share, basic and diluted	The following table shows the calculation of net loss per share (in thousands, except share and per share data): Year Ended Year Ended Period from Numerator: Net loss—basic and diluted $ ) $ ) $ ) Denominator: Weighted average common shares outstanding Less: weighted average common shares subject to repurchase ) ) ) Weighted average common shares outstanding used to compute basic and diluted net loss per share Net loss per share, basic and diluted $ ) $ ) $ )
Schedule of antidilutive securities excluded from calculation of diluted net loss per share	Year Ended Year Ended Period from Convertible preferrd stock — Common stock subject to repurchase Outstanding options Total shares of common stock equivalents

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
Fair Value Measurements (Tables)	Dec. 31, 2016
Fair Value Measurements
Schedule of fair value of assets and liabilities recorded at fair value on a recurring basis, by level within fair value hierarchy	The following tables present information as of December 31, 2016 and 2015 about the Company's assets that are measured at fair value on a recurring basis and indicate the level of the fair value hierarchy the Company utilized to determine such fair values (in thousands): December 31, 2016 Fair Value Measured Using Total (Level 1) (Level 2) (Level 3) Assets Cash equivalents $ $ — $ — $ Marketable securities — — $ $ — $ — $ December 31, 2015 Fair Value Measured Using Total (Level 1) (Level 2) (Level 3) Assets Cash equivalents $ $ — $ — $ Marketable securities — — $ $ — $ — $
Summary of changes in fair value of the Level 3 financial instruments measured on a recurring basis	The following table presents the issuances, changes in fair value, exercise and reclassification of the Company's Level 3 financial instrument which is measured at fair value on a recurring basis (in thousands): Convertible Balance as of December 31, 2014 $ Change in fair value of convertible preferred stock liability through date of Series A second tranche issuance Recognition of fair value upon issuance of second tranche Series A convertible preferred stock ) Balance as of December 31, 2015 $ —
Schedule of fair value of available for sale marketable securities	As of December 31, 2016 and 2015, the fair value of available for sale marketable securities by type of security were as follows (in thousands): December 31, 2016 Amortized Gross Gross Fair U.S. Treasury securities $ $ — $ ) $ December 31, 2015 Amortized Gross Gross Fair U.S. Treasury securities $ $ — $ ) $

Balance Sheet Components (Table

Balance Sheet Components (Tables)	12 Months Ended
Balance Sheet Components (Tables)	Dec. 31, 2016
Balance Sheet Components
Schedule of prepaid and other current assets	December 31, December 31, Prepaid and Other Current Assets Interest receivable $ $ — Prepaid research and development manufacturing expenses — Tenant improvement allowance receivable — Other $ $
Schedule of property and equipment, net	Property and Equipment, net Laboratory equipment $ $ Computer equipment and purchased software Leasehold improvements Construction in progress — Less: accumulated depreciation and amortization ) ) $ $
Schedule of accrued and other liabilities	Accrued and Other Liabilities Accrued clinical trial related $ $ Accrued manufacturing expense Personnel related Deferred rent Accrued legal and accounting Accrued contruction in progress costs — Other accrued expenses $ $
Schedule of other liabilities	Other Liabilities Deferred rent $ $ Shares subject to vesting $ $

Convertible Preferred Stock (Ta

Convertible Preferred Stock (Tables)	12 Months Ended
Convertible Preferred Stock (Tables)	Dec. 31, 2016
Convertible Preferred Stock
Schedule of convertible preferred stock	Convertible preferred stock as of December 31, 2015 consisted of the following (in thousands, except share data): Shares Shares Net Liquidation Series A $ $ Series B Total $ $

Common Stock (Tables)

Common Stock (Tables)	12 Months Ended
Common Stock (Tables)	Dec. 31, 2016
Common Stock.
Schedule of shares of common stock reserved for issuance, on an as-converted basis	December 31, December 31, December 31, Convertible preferred stock — Shares available for future option grants Outstanding options Unvested restricted common stock (founders and early exercise of stock options) Shares reserved for employee stock purchase plan — — Total

Stock Option Plans (Tables)

Stock Option Plans (Tables)	12 Months Ended
Stock Option Plans (Tables)	Dec. 31, 2016
Stock Option Plans
Summary of stock option activity	Options Outstanding Shares Number Weighted- Balance at December 31, 2015 $ Additional shares authorized Options granted ) Options exercised — ) Options forfeited ) Balance at December 31, 2016 $
Summary of information about stock options outstanding	Options Outstanding Options Vested Exercise Price Number Weighted Weighted Number Weighted Weighted $0.28 $ $ $4.65 $ $ $6.75 $ $ $13.34 - 16.37 $ $ $ $ Options Outstanding Options Vested Exercise Price Number Weighted Weighted Number Weighted Weighted $0.28 - $4.65 $ $ $6.75 - $15.79 $ — $ $
Schedule of options outstanding and exercisable that had vested or were expected to vest	Options outstanding and exercisable that had vested or were expected to vest at December 31, 2016 were as follows: Number of shares Weighted Weighted Aggregate Vested $ $ Expected to vest $ $

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	12 Months Ended
Stock-Based Compensation (Tables)	Dec. 31, 2016
Schedule of expenses relating to employee and non-employee stock-based awards	The Company's results of operations include expenses relating to employee and non-employee stock-based awards as follows (in thousands): Year Ended Year Ended Period from Research and development $ $ $ — General and administrative — Total $ $ $ —
Schedule of fair value of share-based awards to employees was estimated using Black Scholes model	Year Ended Year Ended Period from Risk-free interest rate % % % Expected volatility % % % Expected term (in years) Expected divident yield % % %
Non-employees
Schedule of fair value of share-based awards to employees was estimated using Black Scholes model	Year Ended Year Ended Risk-free interest rate 1.90% - 1.94% 1.8% - 2.2% Expected volatility 92.1% - 92.7% 82% - 84.7% Expected term (in years) 8.1 - 8.6 9.1 - 10.0 Expected divident yield 0% 0%

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
Income Taxes (Tables)	Dec. 31, 2016
Income Taxes
Schedule of components of loss before income tax	The components of loss before income tax is as follows (in thousands): 2016 2015 2014 Domestic $ ) $ ) $ ) Foreign ) — — $ ) $ ) $ )
Schedule of reconciliation of the effective tax rate to the U.S. Federal statutory rate	December 31, December 31, December 31, Federal tax benefit at statutory rate % % % State tax, net of Federal benefit Loss due to change in fair value of convertible preferred stock liability — ) — Foreign rate differential ) — — Change in valuation allowance ) ) ) Effective income tax rate % % %
Schedule of principal components of the net deferred tax assets	The principal components of the Company's net deferred tax assets are as follows (in thousands) December 31, December 31, Net operating loss carryforwards $ $ Tax credit carryforwards Capitalized tax assets Accruals Stock compensation Other Total deferred tax assets Valuation allowance ) ) Net deferred tax assets $ — $ —
Schedule of unrecognized tax benefits activity	December 31, December 31, December 31, Unrecognized tax benefits beginning of the period $ $ — $ — Increase related to the prior year — — Increased related to the current year — Unrecognized tax benefits, end of the period $ $ $ —

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
Commitments and Contingencies (Tables)	Dec. 31, 2016
Commitments and Contingencies.
Schedule of future minimum lease payments under the facility lease	As of December 31, 2016, future minimum lease payments under the facility lease were as follows (in thousands): Payments Due by Period Total Less than 2 - 3 years 4 - 5 Years More than Contractual obligations: Operating lease obligations $ $ $ $ $ — Total contractual obligations $ $ $ $ $ —

Quarterly Selected Financial 34

Quarterly Selected Financial Data (unaudited) (Tables)	12 Months Ended
Quarterly Selected Financial Data (unaudited) (Tables)	Dec. 31, 2016
Quarterly Selected Financial Data (unaudited)
Quarterly Selected Financial Data (unaudited)	Quarter Ended December 31, September 30, June 30, March 31, Operating Expenses $ $ $ $ Net loss ) ) ) ) Net loss per share, basic and diluted $ ) $ ) $ ) $ ) Quarter Ended December 31, September 30, June 30, March 31, Operating Expenses $ $ $ $ Net loss ) ) ) ) Net loss per share, basic and diluted $ ) $ ) $ ) $ )

Organization (Details)

Organization (Details)	12 Months Ended
Organization (Details)	Dec. 31, 2016subsidiary
Organization
Number of insignificant subsidiaries	4

Summary of Significant Accoun36

Summary of Significant Accounting Policies - Basis of presentation and credit risk (Details) $ in Thousands	3 Months Ended								11 Months Ended	12 Months Ended
	Dec. 31, 2016USD ($)	Sep. 30, 2016USD ($)	Jun. 30, 2016USD ($)	Mar. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Sep. 30, 2015USD ($)	Jun. 30, 2015USD ($)	Mar. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Dec. 31, 2016USD ($)segmentitem	Dec. 31, 2015USD ($)
Summary of Significant Accounting Policies
Accumulated deficit	$ (67,871)				$ (31,496)					$ (67,871)	$ (31,496)
Cash, cash equivalents and marketable securities	134,900									$ 134,900
Concentrations of Credit Risk and Other Risks and Uncertainties
Number of highly credit qualified financial institutions \| item										2
Net loss	$ (11,086)	$ (10,297)	$ (8,645)	$ (6,347)	$ (6,039)	$ (3,151)	$ (20,232)	$ (1,913)	$ (161)	$ (36,375)	(31,335)
Cash in operations									$ (96)	$ (27,857)	$ (11,328)
Segments
Number of operating segments \| segment										1

Summary of Significant Accoun37

Summary of Significant Accounting Policies - IPO (Details) - USD ($) $ / shares in Units, $ in Millions	Apr. 26, 2016	Mar. 29, 2016
IPO
Initial Public Offering
Share price for IPO (in dollars per share)		$ 15
Issuance of stock (in shares)		4,700,000
Net proceeds from IPO		$ 70.6
Over-Allotment Option
Initial Public Offering
Share price for IPO (in dollars per share)	$ 15
Issuance of stock (in shares)	502,618

Summary of Significant Accoun38

Summary of Significant Accounting Policies - Property and Equipment, Net (Details)	12 Months Ended
	Dec. 31, 2016
Laboratory equipment
Property and Equipment, Net
Estimated Useful lives	5 years
Computer equipment and purchased software
Property and Equipment, Net
Estimated Useful lives	3 years

Net Loss per Share - Net Loss P

Net Loss per Share - Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								11 Months Ended	12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2016	Dec. 31, 2015
Numerator:
Net loss-basic and diluted	$ (11,086)	$ (10,297)	$ (8,645)	$ (6,347)	$ (6,039)	$ (3,151)	$ (20,232)	$ (1,913)	$ (161)	$ (36,375)	$ (31,335)
Denominator:
Weighted average common shares outstanding									641,046	16,188,980	1,269,315
Less: weighted average common shares subject to repurchase									(470,768)	(766,939)	(895,672)
Weighted average common shares used to compute basic and diluted net loss per share									170,278	15,422,041	373,643
Net loss per share, basic and diluted (in dollars per share)	$ (0.55)	$ (0.51)	$ (0.43)	$ (5.39)	$ (13.31)	$ (7.97)	$ (58.42)	$ (6.44)	$ (0.95)	$ (2.36)	$ (83.86)

Net Loss per Share - Anti-Dilut

Net Loss per Share - Anti-Dilutive Securities (Details) - shares	11 Months Ended	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2016	Dec. 31, 2015
Excluded from the calculation of diluted net loss per share, due to anti-dilutive effect
Shares of common stock equivalents	4,196,494	2,962,280	15,983,412
Convertible Preferred Stock.
Excluded from the calculation of diluted net loss per share, due to anti-dilutive effect
Shares of common stock equivalents	3,395,468		14,274,741
Common stock subject to repurchase
Excluded from the calculation of diluted net loss per share, due to anti-dilutive effect
Shares of common stock equivalents	768,706	611,698	924,535
Outstanding options
Excluded from the calculation of diluted net loss per share, due to anti-dilutive effect
Shares of common stock equivalents	32,320	2,350,582	784,136

Fair Value Measurements - Recur

Fair Value Measurements - Recurring (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2016	Nov. 26, 2014
Assets
Marketable securities	$ 90,281	$ 129,846
U.S. Treasury securities
Assets
Marketable securities	90,281	129,846
Recurring
Assets
Cash equivalents	3,245	2,999
Marketable securities	90,281	129,846
Total Assets	93,526	132,845
Recurring \| Level 1
Assets
Cash equivalents	3,245	2,999
Marketable securities	90,281	129,846
Total Assets	93,526	$ 132,845
Series A convertible preferred stock
Liabilities
Convertible preferred stock liability			$ 2,600
Series A convertible preferred stock \| Obligation to issue second tranche
Issuances, changes in fair value, exercise and reclassification of the Level 3 financial instrument
Balance as of the beginning of the period	2,600
Change in fair value of convertible preferred stock liability through date of Series A second tranche issuance	17,600
Recognition of fair value upon issuance of second tranche Series A convertible preferred stock	$ (20,200)

Fair Value Measurements - Avail

Fair Value Measurements - Available For Sale (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Fair value of available for sale marketable securities
Fair Value	$ 129,846	$ 90,281
U.S. Treasury securities
Fair value of available for sale marketable securities
Amortized Cost	129,885	90,326
Gross Unrealized Losses	(39)	(45)
Fair Value	$ 129,846	$ 90,281

License and Collaboration Agr43

License and Collaboration Agreements (Details) - USD ($)	12 Months Ended
License and Collaboration Agreements (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015	Feb. 28, 2017	Feb. 13, 2017
Scripps Research Institute
License and Collaboration Agreements
Milestone payments made	$ 0
Vernalis (R&D) Limited \| Subsequent Events
License and Collaboration Agreements
Milestone payments made			$ 3,000,000	$ 0
Licensing Agreement \| Scripps Research Institute
License and Collaboration Agreements
Minimum annual fee		$ 25,000
Aggregate potential milestone payments	$ 2,600,000
Period of written notice to terminate	90 days
Licensing Agreement \| Scripps Research Institute \| Research and development
License and Collaboration Agreements
One-time cash payment		$ 10,000
Licensing Agreement \| Vernalis (R&D) Limited
License and Collaboration Agreements
Period of written notice to terminate	90 days
Licensing Agreement \| Vernalis (R&D) Limited \| Minimum
License and Collaboration Agreements
Aggregate potential milestone payments	$ 200,000,000
Licensing Agreement \| Vernalis (R&D) Limited \| Research and development
License and Collaboration Agreements
One-time cash payment	$ 1,000,000

Balance Sheet Components - Prep

Balance Sheet Components - Prepaid and Other Current Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Prepaid and Other Current Assets
Interest Receivable	$ 365
Prepaid research and development manufacturing expenses		$ 722
Tenant improvement allowance receivable		347
Other	772	208
Total of prepaid and other current assets	$ 1,137	$ 1,277

Balance Sheet Components - Prop

Balance Sheet Components - Property and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Property and Equipment, net
Property and equipment, gross	$ 3,977	$ 1,980
Less: accumulated depreciation and amortization	(729)	(135)
Property and equipment, net	3,248	1,845
Laboratory equipment
Property and Equipment, net
Property and equipment, gross	1,868	829
Computer equipment and purchased software
Property and Equipment, net
Property and equipment, gross	58	18
Leasehold improvements
Property and Equipment, net
Property and equipment, gross	$ 2,051	74
Construction in progress
Property and Equipment, net
Property and equipment, gross		$ 1,059

Balance Sheet Components - Accr

Balance Sheet Components - Accrued and Other Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Accrued and Other Liabilities
Accrued clinical trial related	$ 1,617	$ 376
Accrued Manufacturing Expense	955	12
Personnel related	526	305
Deferred rent	378	223
Accrued legal and accounting	255	314
Accrued construction in progress costs		101
Other accrued expenses	313	164
Accrued Liabilities and Other Liabilities, Total	$ 4,044	$ 1,495

Balance Sheet Components - Othe

Balance Sheet Components - Other Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Other Liabilities
Deferred rent	$ 1,370	$ 642
Shares subject to vesting	35	68
Total of other liabilities	$ 1,405	$ 710

Convertible Preferred Stock (De

Convertible Preferred Stock (Details) $ in Thousands	Mar. 29, 2016shares	Dec. 31, 2016itemshares	Dec. 31, 2015USD ($)shares	Dec. 31, 2014shares	Nov. 26, 2014shares
Convertible Preferred Stock
Number of classes of stock authorized \| item		2
Convertible preferred stock
Shares Authorized		0	14,274,741	8,921,438
Shares Issued		0	14,274,741
Net Carrying Value \| $			$ 125,780
Liquidation Value \| $			$ 108,500
Shares Outstanding		0	14,274,741
Conversion
Number of common stock issued with the conversion of the preferred stock (in shares)	14,274,741
Preferred stock conversion ratio	1
Series A convertible preferred stock
Convertible preferred stock
Shares Authorized			8,921,429		8,921,438
Shares Issued			8,921,429
Net Carrying Value \| $			$ 50,941
Liquidation Value \| $			$ 33,500
Series B convertible preferred stock
Convertible preferred stock
Shares Authorized			5,353,312
Shares Issued			5,353,312
Net Carrying Value \| $			$ 74,839
Liquidation Value \| $			$ 75,000

Convertible Preferred Stock L49

Convertible Preferred Stock Liability (Details) $ / shares in Units, $ in Thousands	Jun. 10, 2015	Nov. 26, 2014USD ($)itemshares	Jun. 30, 2015USD ($)$ / sharesshares	Jan. 31, 2015USD ($)shares	Mar. 31, 2015	Jun. 30, 2015USD ($)	Dec. 31, 2014USD ($)shares	Dec. 31, 2015USD ($)shares	Dec. 31, 2014shares	Dec. 31, 2016shares
Convertible preferred stock
Shares Authorized \| shares							8,921,438	14,274,741	8,921,438	0
Net proceeds							$ 12,611	$ 95,569
Change in fair value of convertible preferred stock liability								$ 17,600
Series A convertible preferred stock
Convertible preferred stock
Shares Authorized \| shares		8,921,438						8,921,429
Issuance of stock (in shares) \| shares		3,395,468	4,460,715	1,065,246			3,395,468	5,525,961
Net proceeds		$ 12,600	$ 16,700	$ 4,000
Number of defined triggers for issuance of additional shares to first tranche investors on the same terms \| item		3
Convertible preferred stock liability		$ 2,600
Change in fair value of convertible preferred stock liability						$ 17,600
Reclassification of liability to convertible preferred stock			$ 20,200
Series A convertible preferred stock \| Obligation to issue second tranche
Convertible preferred stock
Fixed price for second tranche obligation (in dollars per share) \| $ / shares			$ 3.755
Assumed term	2 years				9 months				1 year
Interest rate (as a percent)	0.75%				0.20%				0.13%
Volatility (as a percent)	75.00%				85.00%				85.00%

Common Stock (Details)

Common Stock (Details)	11 Months Ended	12 Months Ended
Common Stock (Details)	Dec. 31, 2014shares	Dec. 31, 2016USD ($)Voteshares	Dec. 31, 2015shares
Common Stock
Common stock, shares authorized for issuance		290,000,000	20,000,000
Preferred stock, shares authorized for issuance		10,000,000	0
Number of votes per share of common stock \| Vote		1
Dividends on common stock \| $		$ 0
Shares of common stock reserved for issuance, on an as-converted basis
Convertible preferred stock, shares authorized	8,921,438	0	14,274,741
Shares available for future option grants	837,547	2,475,600	2,559,499
Outstanding options	32,320	2,350,582	784,136
Unvested restricted common stock (founders and early exercise of stock options)	768,706	611,698	924,535
Shares reserved for employee stock purchase plan		200,000
Total	10,560,011	5,637,880	18,542,911
Common Stock
Common Stock
Shares of common stock sold to founders	1,046,749		384,866

Stock Option Plans - Stock Opti

Stock Option Plans - Stock Option Activity (Details) - $ / shares	1 Months Ended		12 Months Ended
	Mar. 31, 2016	Feb. 28, 2014	Dec. 31, 2016
Shares Available for Grant
Beginning balance			2,559,499
Ending balance			2,475,600
Number of Options
Beginning balance			784,136
Ending balance			2,350,582
2016 Plan
Stock Option Plans
Vesting period	4 years
Maximum exercise term	10 years
Exercise price of common stock of its fair value (as a percent)	100.00%
Shares Available for Grant
Beginning balance			2,559,499
Shares authorized for plan			1,496,001
Granted			(1,813,400)
Forfeited			233,500
Ending balance			2,475,600
Number of Options
Beginning balance			784,136
Granted			1,813,400
Exercised			(13,454)
Forfeited			(233,500)
Ending balance			2,350,582
Weighted Average Exercise Price
Beginning balance (in dollars per share)			$ 4.09
Granted (in dollars per share)			15.09
Exercised (in dollars per share)			0.28
Forfeited (in dollars per share)			11.35
Ending balance (in dollars per share)			$ 11.88
2014 Plan
Stock Option Plans
Vesting period		4 years
Maximum exercise term		10 years
Exercise price of common stock of its fair value (as a percent)		100.00%
Maximum number of options that may be re-issued under the 2016 plan	1,136,229

Stock Option Plan - Exercise Pr

Stock Option Plan - Exercise Price Range (Details) - $ / shares	11 Months Ended	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2016	Dec. 31, 2015
Information about stock options outstanding
Options Outstanding, Number		2,350,582	784,136
Options Outstanding, Weighted Average Remaining Contractual Life		9 years 2 months 16 days	9 years 7 months 17 days
Weighted average exercise price of options outstanding (in dollars per share)		$ 11.88	$ 4.09
Options Vested, Number		397,486	9,637
Options Vested, Weighted Average Remaining Contractual Life		8 years 10 months 2 days	9 years 22 days
Weighted average exercise price of options vested (in dollars per share)		$ 8.02	$ 0.28
Weighted average grant date fair value of options granted (in dollars per share)	$ 0.22	10.78	4.37
$ 0.28
Information about stock options outstanding
Exercise Price, low end of range (in dollars per share)		$ 0.28
Options Outstanding, Number		419,682
Options Outstanding, Weighted Average Remaining Contractual Life		8 years 5 months 16 days
Weighted average exercise price of options outstanding (in dollars per share)		$ 0.28
Options Vested, Number		159,732
Options Vested, Weighted Average Remaining Contractual Life		8 years 5 months 9 days
Weighted average exercise price of options vested (in dollars per share)		$ 0.28
$ 4.65
Information about stock options outstanding
Exercise Price, low end of range (in dollars per share)		$ 4.65
Options Outstanding, Number		144,500
Options Outstanding, Weighted Average Remaining Contractual Life		8 years 9 months 22 days
Weighted average exercise price of options outstanding (in dollars per share)		$ 4.65
Options Vested, Number		42,449
Options Vested, Weighted Average Remaining Contractual Life		8 years 9 months 22 days
Weighted average exercise price of options vested (in dollars per share)		$ 4.65
$ 6.75
Information about stock options outstanding
Exercise Price, low end of range (in dollars per share)		$ 6.75
Options Outstanding, Number		5,000
Options Outstanding, Weighted Average Remaining Contractual Life		8 years 10 months 13 days
Weighted average exercise price of options outstanding (in dollars per share)		$ 6.75
Options Vested, Number		1,438
Options Vested, Weighted Average Remaining Contractual Life		8 years 10 months 13 days
Weighted average exercise price of options vested (in dollars per share)		$ 6.75
$13.34 - 16.37
Information about stock options outstanding
Exercise Price, low end of range (in dollars per share)		13.34
Exercise Price, high end of range (in dollars per share)		$ 16.37
Options Outstanding, Number		1,781,400
Options Outstanding, Weighted Average Remaining Contractual Life		9 years 5 months 1 day
Weighted average exercise price of options outstanding (in dollars per share)		$ 15.21
Options Vested, Number		193,867
Options Vested, Weighted Average Remaining Contractual Life		9 years 2 months 5 days
Weighted average exercise price of options vested (in dollars per share)		$ 15.14
$0.28 - 4.65
Information about stock options outstanding
Exercise Price, low end of range (in dollars per share)			0.28
Exercise Price, high end of range (in dollars per share)			$ 4.65
Options Outstanding, Number			629,136
Options Outstanding, Weighted Average Remaining Contractual Life			9 years 6 months 15 days
Weighted average exercise price of options outstanding (in dollars per share)			$ 1.28
Options Vested, Number			9,637
Options Vested, Weighted Average Remaining Contractual Life			9 years 22 days
Weighted average exercise price of options vested (in dollars per share)			$ 0.28
$6.75 - 15.79
Information about stock options outstanding
Exercise Price, low end of range (in dollars per share)			6.75
Exercise Price, high end of range (in dollars per share)			$ 15.79
Options Outstanding, Number			155,000
Options Outstanding, Weighted Average Remaining Contractual Life			10 years
Weighted average exercise price of options outstanding (in dollars per share)			$ 15.50

Stock Option Plan - Vested or E

Stock Option Plan - Vested or Expected to Vest (Details) - USD ($)	11 Months Ended	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2016	Dec. 31, 2015
Options outstanding and exercisable
Vested, Number of Shares (in shares)		397,486
Vested, Weighted Average Exercise Price (in dollars per share)		$ 8.02
Vested, Weighted Average Remaining Contractual Life		8 years 10 months 2 days
Vested, Aggregate Intrinsic Value		$ 2,660,000
Expected to vest, Number of Shares (in shares)		1,953,096
Expected to vest, Weighted Average Exercise Price (in dollars per share)		$ 12.66
Expected to vest, Weighted Average Remaining Contractual Life		9 years 3 months 7 days
Expected to vest, Aggregate Intrinsic Value		$ 4,869,000
Fair value of common stock (in dollars per share)		$ 14.30
Aggregate intrinsic value of stock options exercised	$ 0	$ 216,000	$ 714,000
Fair value of options vested	$ 100	$ 3,195,000	$ 75,000

Stock-Based Compensation - Expe

Stock-Based Compensation - Expense Allocation (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Stock-based compensation
Stock-based compensation expense	$ 3,828	$ 428
Research and development
Stock-based compensation
Stock-based compensation expense	1,685	292
General and administrative
Stock-based compensation
Stock-based compensation expense	$ 2,143	$ 136

Stock Based Compensation -Valua

Stock Based Compensation -Valuation Assumptions Employees (Details) - USD ($)	11 Months Ended	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2016	Dec. 31, 2015
Weighted-average assumptions used to estimate fair value of share-based awards
Risk-free interest rate	1.70%	1.60%	1.70%
Expected volatility	97.00%	84.60%	83.30%
Expected term (in years)	6 years 1 month 6 days	6 years	6 years 1 month 6 days
Expected dividend yield	0.00%	0.00%	0.00%
Unrecognized compensation expense		$ 18.5	$ 4,700,000
Expected period for recognizing compensation expense		3 years 3 months 11 days	3 years 7 months 21 days

Stock Based Compensation -Val56

Stock Based Compensation -Valuation Assumptions Non-Employees (Details) - USD ($)	11 Months Ended	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2016	Dec. 31, 2015
Stock Option Plans
Stock-based compensation expense		$ 3,828,000	$ 428,000
Weighted-average assumptions used to estimate fair value of share-based awards
Expected term (in years)	6 years 1 month 6 days	6 years	6 years 1 month 6 days
Expected dividend yield	0.00%	0.00%	0.00%
Non-employee stock options
Stock Option Plans
Stock-based compensation expense		$ 142,500	$ 42,848
Weighted-average assumptions used to estimate fair value of share-based awards
Risk-free interest rate, minimum		1.90%	1.80%
Risk-free interest rate, maximum		1.94%	2.20%
Expected Volatility, minimum		92.10%	82.00%
Expected Volatility, maximum		92.70%	84.70%
Expected dividend yield		0.00%	0.00%
Non-employee stock options \| Minimum
Weighted-average assumptions used to estimate fair value of share-based awards
Expected term (in years)		8 years 1 month 6 days	9 years 1 month 6 days
Non-employee stock options \| Maximum
Weighted-average assumptions used to estimate fair value of share-based awards
Expected term (in years)		8 years 7 months 6 days	10 years

Income Taxes - Operating loss c

Income Taxes - Operating loss carryforwards (Details) - USD ($) $ in Thousands	Jan. 31, 2014	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2016	Dec. 31, 2015
Net operating loss carryforwards
Income tax benefit	$ 0	$ 0	$ 0	$ 0	$ 0
Federal
Net operating loss carryforwards
NOL carryforwards				20,000
State
Net operating loss carryforwards
NOL carryforwards				$ 45,000

Income Taxes - Tax credit carry

Income Taxes - Tax credit carry forwards (Details) - USD ($) $ in Millions	Dec. 31, 2016	Apr. 30, 2016	Dec. 31, 2015
Tax Credit Carryforward [Line Items]
Common stock, shares issued	20,922,428		1,431,615
Research and development credits \| Federal
Tax Credit Carryforward [Line Items]
Research and development tax credit carryforwards	$ 1.3
Research and development credits \| State
Tax Credit Carryforward [Line Items]
Research and development tax credit carryforwards	$ 1.7
IPO
Tax Credit Carryforward [Line Items]
Common stock, shares issued		5,200,000

Income Taxes - Components of lo

Income Taxes - Components of loss before income tax (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Income Taxes
Domestic	$ (11,375)	$ (31,335)	$ (161)
Foreign	(25,000)
Total	$ (36,375)	$ (31,335)	$ (161)

Income Taxes - Reconciliation o

Income Taxes - Reconciliation of effective tax rate (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Reconciliation of the effective tax rate to the U.S. Federal statutory rate
Federal tax benefit at statutory rate	34.00%	34.00%	34.00%
State tax, net of Federal benefit	8.00%	3.00%	6.00%
Loss due to change in fair value of convertible preferred stock liability		(19.00%)
Foreign rate differential	(23.00%)
Change in valuation allowance	(19.00%)	(18.00%)	(40.00%)
Effective income tax rate	0.00%	0.00%	0.00%
Increased in valuation allowance	$ 7	$ 5.8

Income Taxes - Deferred tax ass

Income Taxes - Deferred tax assets net (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Deferred tax assets:
Net operating loss carryforwards	$ 9,339	$ 4,671
Tax credit carryforwards	1,960	445
Capitalized tax assets	241	528
Accruals	230	108
Stock compensation	954	43
Other	67	71
Total deferred tax assets	12,791	5,866
Valuation allowance	(12,791)	(5,866)
Net deferred tax assets	$ 0	$ 0

Income Taxes - Unrecognized tax

Income Taxes - Unrecognized tax benefits (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Summary of unrecognized tax benefits
Unrecognized tax benefits beginning of the period	$ 135
Increase related to the prior year	6
Increased related to the current year	463	$ 135
Unrecognized tax benefits, end of the period	$ 604	$ 135

Commitments and Contingencies63

Commitments and Contingencies (Details)	1 Months Ended	12 Months Ended		20 Months Ended
Commitments and Contingencies (Details)	Jan. 31, 2015ft²	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Aug. 31, 2016ft²
Facility Lease
Landlord Provided Free Rent And Lease Incentives		$ 1,900,000
Rent expense		584,000	$ 347,000
Operating lease obligations
Total		4,745,000
Less than 1 Year		1,112,000
2-3 years		2,321,000
4-5 years		1,312,000
Contractual obligations
Total		4,745,000
Less than 1 Year		1,112,000
2-3 years		2,321,000
4-5 years		$ 1,312,000
Facilities lease \| Office and laboratory space in Burlingame, California
Facility Lease
Area of leased facility \| ft²	8,138
Additional area of lease \| ft²				28,633
Lease term	1 year
Lease agreement, right to extend the term		3 years

Commitments and Contingencies -

Commitments and Contingencies - Line of Credit (Details) $ in Millions	Aug. 31, 2015USD ($)
Line of credit
Security deposit	$ 0.1
Secured debt
Line of credit
Line of credit	$ 0.1

Quarterly Selected Financial 65

Quarterly Selected Financial Data (unaudited) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								11 Months Ended	12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2016	Dec. 31, 2015
Quarterly Selected Financial Data (unaudited)
Operating Expenses	$ 11,249	$ 10,476	$ 8,825	$ 6,426	$ 6,104	$ 3,120	$ 2,332	$ 2,214	$ 161	$ 36,976	$ 13,770
Net loss	$ (11,086)	$ (10,297)	$ (8,645)	$ (6,347)	$ (6,039)	$ (3,151)	$ (20,232)	$ (1,913)	$ (161)	$ (36,375)	$ (31,335)
Net loss per share, basic and diluted (in dollars per share)	$ (0.55)	$ (0.51)	$ (0.43)	$ (5.39)	$ (13.31)	$ (7.97)	$ (58.42)	$ (6.44)	$ (0.95)	$ (2.36)	$ (83.86)

Subsequent Events (Details)

Subsequent Events (Details) - USD ($) $ in Millions	Feb. 28, 2017	Feb. 13, 2017
Subsequent Events \| Vernalis (R&D) Limited
Subsequent Events
Milestone payments made	$ 3	$ 0

Uncategorized Items - crvs-2016

Label	Element	Value
Stock Issued During Period, Value, Issued for Services	us-gaap_StockIssuedDuringPeriodValueIssuedForServices	$ 2,000
Retained Earnings [Member]
Net Income (Loss) Attributable to Parent	us-gaap_NetIncomeLoss	(161,000)
Additional Paid In Capital [Member]
Stock Issued During Period, Value, Issued for Services	us-gaap_StockIssuedDuringPeriodValueIssuedForServices	2,000
Series Convertible Preferred Stock [Member]
Temporary Equity, Stock Issued During Period, Value, New Issues	us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues	$ 10,011,000